Takeda Pharmaceutical Co. Ltd. Sponsored ADR Forecast, price target & analysts
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Target price 2024 - Analyst rating & recommendation
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Classifications & Recommendation:
Takeda Pharmaceutical Co. Ltd. Sponsored ADR Price Target
| Target Price | $15.42 |
| Price | $13.27 |
| Potential |
16.20%
register free of charge
|
| Number of Estimates | 13 |
|
13 Analysts have issued a price target Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2025 .
The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR target price is $15.42.
This is
16.20%
register free of charge
$17.97
35.43%
register free of charge
$13.56
2.16%
register free of charge
|
|
| A rating was issued by 15 analysts: 6 Analysts recommend Takeda Pharmaceutical Co. Ltd. Sponsored ADR to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock has an average upside potential 2025 of
16.20%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 29.49 | 29.42 |
| 0.78% | 0.24% | |
| EBITDA Margin | 29.51% | 25.75% |
| 10.15% | 12.73% | |
| Net Margin | 3.44% | 2.99% |
| 57.00% | 13.10% |
13 Analysts have issued a sales forecast Takeda Pharmaceutical Co. Ltd. Sponsored ADR 2025 . The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA forecast 2025. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Takeda Pharmaceutical Co. Ltd. Sponsored ADR Analysts have issued a net profit forecast 2025. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.32 | 0.28 |
| 57.33% | 12.50% | |
| P/E | 47.82 | |
| EV/Sales | 2.43 |
8 Analysts have issued a Takeda Pharmaceutical Co. Ltd. Sponsored ADR forecast for earnings per share. The average Takeda Pharmaceutical Co. Ltd. Sponsored ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Takeda Pharmaceutical Co. Ltd. Sponsored ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Takeda Pharmaceutical Co. Ltd. Sponsored ADR...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
